Clinical Trials
12 trialsNCT07227402 2026-06-04
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07405164 2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07489495 2026-05-29
LITESPARK-034
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07049926 2026-05-26
MK-3475-03C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04846920 2026-05-22
MK-6482-018
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT07023432 2026-05-22
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07593040 2026-05-20
Moonlanding
Vall d'Hebron Institute of Oncology
Phase 2 Not yet recruiting
NCT04626479 2026-05-18
MK-3475-03A
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT05239728 2026-05-15
MK-6482-022
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04195750 2026-05-14
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04626518 2026-05-06
KEYMAKER-U03
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT04736706 2026-05-06
MK-6482-012
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting